Published in J Natl Cancer Inst on November 06, 2002
"Drivers" of translational cancer epidemiology in the 21st century: needs and opportunities. Cancer Epidemiol Biomarkers Prev (2013) 1.72
Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol (2006) 1.46
Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol (2006) 1.33
Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck (2010) 1.16
Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer? J Natl Cancer Inst (2002) 1.16
Human Papillomaviruses and genital co-infections in gynaecological outpatients. BMC Infect Dis (2009) 1.06
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One (2013) 1.04
Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Mol Cancer (2010) 0.98
Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: a case control study. Infect Agent Cancer (2006) 0.96
Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. Int J Cancer (2013) 0.96
Infection and cervical neoplasia: facts and fiction. Int J Clin Exp Pathol (2008) 0.94
Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol (2004) 0.94
Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine. Future Virol (2012) 0.92
Multifactorial etiology of cervical cancer: a hypothesis. MedGenMed (2005) 0.90
Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol Lett (2015) 0.90
Age of diagnosis of squamous cell cervical carcinoma and early sexual experience. Cancer Epidemiol Biomarkers Prev (2009) 0.90
HPV infection: immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol (2013) 0.89
Cervical screening within HIV care: findings from an HIV-positive cohort in Ukraine. PLoS One (2012) 0.88
Vaccines for cervical cancer. Epidemiol Infect (2006) 0.88
Formation of 8-nitroguanine, a nitrative DNA lesion, in inflammation-related carcinogenesis and its significance. Environ Health Prev Med (2009) 0.84
Association of Chlamydia trachomatis infection and herpes simplex virus type 2 serostatus with genital human papillomavirus infection in men: the HPV in men study. Sex Transm Dis (2013) 0.84
Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine. Int J Womens Health (2010) 0.84
Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2. Virus Res (2010) 0.84
Human papillomavirus genotyping and integration in ovarian cancer Saudi patients. Virol J (2013) 0.83
Detection of Human Papilloma Virus (HPV) in oral mucosa of women with cervical lesions and their relation to oral sex practices. Infect Agent Cancer (2010) 0.83
Expression of the CXCL12/CXCR4 and CXCL16/CXCR6 axes in cervical intraepithelial neoplasia and cervical cancer. Chin J Cancer (2012) 0.83
Cancer of the cervix - from bleak past to bright future; a review, with an emphasis on cancer of the cervix in malaysia. Malays J Med Sci (2003) 0.82
Epidemiological aspects of genital warts in romania - a 2012 retrospective survey. Maedica (Buchar) (2014) 0.81
Opportunistic intestinal infections and risk of colorectal cancer among people with AIDS. AIDS Res Hum Retroviruses (2012) 0.81
High co-prevalence of genogroup 1 TT virus and human papillomavirus is associated with poor clinical outcome of laryngeal carcinoma. J Clin Pathol (2005) 0.80
A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J Virol (2012) 0.80
Oral Sex and HPV: Population Based Indications. Indian J Otolaryngol Head Neck Surg (2012) 0.80
Human papillomavirus genotypes in penile cancers from Japanese patients and HPV-induced NF-κB activation. Oncol Lett (2010) 0.80
Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening. Br J Cancer (2008) 0.80
Regulation of inflammatory pathways in cancer and infectious disease of the cervix. Scientifica (Cairo) (2012) 0.79
Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol (2009) 0.79
Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa. PLoS One (2017) 0.79
Biomarkers of oxidant load and type-specific clearance of prevalent oncogenic human papillomavirus infection: markers of immune response? Int J Cancer (2011) 0.78
Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. J Gen Virol (2015) 0.78
Seminal plasma induces the expression of IL-1α in normal and neoplastic cervical cells via EP2/EGFR/PI3K/AKT pathway. J Mol Signal (2014) 0.77
Herpes simplex virus type-2 seropositivity among ever married women in South and north Vietnam: a population-based study. Sex Transm Dis (2009) 0.77
Prevalence of herpes simplex virus type 2 and risk factors associated with this infection in women in southern Brazil. Rev Inst Med Trop Sao Paulo (2013) 0.77
Human papillomavirus infection induces NF-κB activation in cervical cancer: A comparison with penile cancer. Oncol Lett (2010) 0.76
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int J Cancer (2016) 0.76
Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions. EPMA J (2014) 0.76
Interleukin-1 beta-511 polymorphism and risk of cervical cancer. J Korean Med Sci (2007) 0.76
Tumour virology in the era of high-throughput genomics. Philos Trans R Soc Lond B Biol Sci (2017) 0.75
Current issues facing the introduction of human papillomavirus vaccine in malaysia. Malays Fam Physician (2007) 0.75
The interaction between human papillomavirus and other viruses. Virus Res (2016) 0.75
Seminal Fluid-Mediated Inflammation in Physiology and Pathology of the Female Reproductive Tract. J Immunol Res (2016) 0.75
Analysis of human papillomavirus and herpes simplex virus genus -2 from patients with cervical cancer in isfahan, iran. Mater Sociomed (2014) 0.75
Participation rates in cervical cancer screening: experience in rural Northern Greece. Hippokratia (2011) 0.75
Associations between sexually transmitted infections, high-risk human papillomavirus infection, and abnormal cervical Pap smear results in OB/GYN outpatients. J Gynecol Oncol (2016) 0.75
Serological test results of sexually transmitted diseases in patients with condyloma acuminata. Postepy Dermatol Alergol (2015) 0.75
Socio-Demographic, Reproductive and Clinical Profile of Women Diagnosed with Advanced Cervical Cancer in a Tertiary Care Institute of Delhi. J Obstet Gynaecol India (2016) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer (2007) 10.29
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis (2007) 6.86
Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst (2005) 6.69
Chapter 1: HPV in the etiology of human cancer. Vaccine (2006) 6.61
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer (2011) 5.43
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA (2007) 4.66
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst (2007) 4.55
Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis (2010) 4.42
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer (2009) 4.28
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS (2006) 3.76
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine (2006) 3.72
Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol (2011) 3.58
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev (2005) 3.40
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer (2012) 3.35
Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev (2009) 3.33
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer (2006) 3.27
Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology (2007) 3.22